Pliant Therapeutics Competitors, Revenue, Alternatives and Pricing
Overview
Industry Ranking
Growjo 10k Ranking
Estimated Revenue & Financials
- Pliant Therapeutics's estimated annual revenue is currently $15.3M per year.
- Pliant Therapeutics received $62.0M in venture funding in July 2018.
- Pliant Therapeutics's estimated revenue per employee is $201,000
- Pliant Therapeutics's total funding is $207.4M.
Employee Data
- Pliant Therapeutics has 76 Employees.
- Pliant Therapeutics grew their employee count by 25% last year.
- Pliant Therapeutics currently has 23 job openings.
Pliant Therapeutics Competitors
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
|---|---|---|---|---|---|---|
| $15.3M | 76 | 3% | N/A | - | N/A | |
| N/A | 125 | N/A | N/A | - | N/A | |
| $13.1M | 65 | 23% | N/A | - | N/A | |
| $53.1M | 264 | N/A | N/A | - | N/A | |
| $10.1M | 50 | 4% | N/A | - | N/A | |
| $13.5M | 67 | 20% | N/A | - | N/A | |
| $62.1M | 309 | 10% | N/A | - | N/A | |
| $22.5M | 112 | 5% | N/A | - | N/A | |
| N/A | 17 | N/A | N/A | - | N/A | |
| $69.5M | 346 | 2% | N/A | - | N/A |
What Is Pliant Therapeutics?
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF- modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant's co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
keywords:N/A76
Number of Employees
$15.3M
Revenue (est)
23
Current Jobs
25%
Employee Growth %
$207.4M
Total Funding
N/A
Valuation
N/A
Accelerator
N/A
Type
Pliant Therapeutics News
SOUTH SAN FRANCISCO, June 27, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on ...
He currently serves on the board of directors of Pliant Therapeutics. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from ...
SOUTH SAN FRANCISCO, Calif., April 9, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a biotechnology company focused on discovering, ...
Pliant Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-02-19 | $45.0M | A | Third Rock Ventures, LLC | Article |
| 2018-07-17 | $62.0M | B | Cowen Healthcare Investments | Article |
Pliant Therapeutics Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2016-04-29 | Hans Hull | Chief Business Officer | Article |
| 2017-01-06 | Rik Derynck | Scientific Founder | Article |
| 2017-09-27 | Katerina Leftheris | Vice President of Chemistry | Article |
| 2018-05-09 | Hoyoung Huh | Chairman | Article |
| 2019-01-04 | Keith Cummings | Chief Financial Officer | Article |